Results of a Phase I Trial of Induction Cisplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib with Radiotherapy for Advanced Head and Neck Cancer by Ahn, P. H. et al.
Bodine Journal
Volume 3
Issue 1 Fall 2010 Article 22
2010
Results of a Phase I Trial of Induction Cisplatin,
Docetaxel, 5-FU and Erlotinib Followed by
Cisplatin, Bevacizumab and Erlotinib with
Radiotherapy for Advanced Head and Neck
Cancer
P. H. Ahn
Thomas Jefferson University and Hospitals
M. Machtay
University Hospitals Case Western Reserve University
P. R. Anné
Thomas Jefferson University and Hospitals
E. Wuthrick
Thomas Jefferson University and Hospitals
W. M. Keane
Thomas Jefferson University and Hospitals
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Bodine Journal by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Ahn, P. H.; Machtay, M.; Anné, P. R.; Wuthrick, E.; Keane, W. M.; Cognetti, D.; Dicker, A. P.; and Axelrod, R. S. (2010) "Results of a
Phase I Trial of Induction Cisplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib with
Radiotherapy for Advanced Head and Neck Cancer," Bodine Journal: Vol. 3: Iss. 1, Article 22.
Available at: http://jdc.jefferson.edu/bodinejournal/vol3/iss1/22
See next page for additional authors
Follow this and additional works at: http://jdc.jefferson.edu/bodinejournal
Part of the Oncology Commons
Results of a Phase I Trial of Induction Cisplatin, Docetaxel, 5-FU and
Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib with
Radiotherapy for Advanced Head and Neck Cancer
Authors
P. H. Ahn, M. Machtay, P. R. Anné, E. Wuthrick, W. M. Keane, D. Cognetti, A. P. Dicker, and R. S. Axelrod
This accepted abstract is available in Bodine Journal: http://jdc.jefferson.edu/bodinejournal/vol3/iss1/22
BODINEJOURNAL 21
Results of a Phase I Trial of Induction 
Cisplatin, Docetaxel, 5-FU and Erlotinib 
Followed by Cisplatin, Bevacizumab and 
Erlotinib with Radiotherapy for Advanced 
Head and Neck Cancer
Background
A phase I trial of induction cisplatin, docetaxel, 5-FU and erlotinib 
(TPF-E) followed by cisplatin, bevacizumab and erlotinib (PA-E) 
with radiotherapy (XRT) for advanced head and neck cancer (HNC) 
was conducted.
Methods
Eligible patients had stage IVA-C HNC, with performance status 
(PS) 0 or 1, good hematologic and renal reserve, and no pre-existing 
grade 2 cardiovascular comorbidities. Two cycles of induction q3 
week TPF-E were administered, with 75 mg/m2 cisplatin, 75 mg/m2 
docetaxel, and 750 mg/m2 days 1-4 CI 5-FU during each cycle. Initial 
dose of erlotinib was 50mg daily from start of induction chemotherapy 
until radiotherapy completion. Dose escalation levels of erlotinib 
with 100mg and 150mg were performed. XRT was administered 
with concurrent cisplatin 30mg/m2 weekly and bevacizumab 10 mg/
kg q2 weeks. Dose limiting toxicity (DLTs) were defined as Grade 
4-5 toxicity or Grade 3 toxicity attributable to erlotinib and requiring 
hospitalization. This trial was supported by a grant from Genentech.
Results
13 patients with previously untreated local-regionally advanced 
(11 patients) or previously untreated locoregional disease with 
oligometastatic disease (two patients) HNC were enrolled. Two 
patients in cohort 1 (erlotinib 50mg) did not complete XRT due 
to noncompliance or progression. One patient received induction 
Avastin with TPF-E and developed GI perforation, prompting 
deletion of Avastin from induction TPF-E. Four of five evaluable 
patients in cohort 1 completed both TPF-E and XRT with PA-E 
(erlotinib 50mg; erlotinib discontinued due to intractable diarrhea). 
Three of four patients in cohort 2 completed all therapy (100mg; 
patient with DLT of colonic perforation in diverticulum during 
induction TPF-E).  Zero of one patient in cohort 3 completed all 
therapy (150mg; diarrhea, abscess and decreased PS). There were no 
Grade 5 toxicities; one patient in cohort 1 died soon after treatment 
with no cause on autopsy. One patient in the final regimen had 
significant gastrointestinal complications (perforation). At median 
13.2 month follow-up, 7 patients (54%) are alive with no evidence of 
disease, and 2 (15%) are alive with recurrent but stable disease.
Conclusion
Erlotinib in combination with induction TPF followed by erlotinib 
with XRT, cisplatin and bevacizumab is active but toxic. MTD was 
reached at 100 mg erlotinib, but overall rates of treatment compliance 
were low, in part due to gastrointestinal toxicities and poor PS after 
induction therapy. Gastrointestinal toxicity proved to be the most 
frequent reason for morbidity and DLT in this study. 
This trial was supported by a grant from Genentech.
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